Cargando…

Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience

PURPOSE: This study was conducted to evaluate the incidence of prostate cancer (PCa) in Iranian male patients with increased prostate-specific antigen (PSA), and normal or abnormal digital rectal examination (DRE) that underwent prostate biopsy. MATERIALS AND METHODS: From March 2006 to April 2009,...

Descripción completa

Detalles Bibliográficos
Autores principales: Moslemi, Mohammad Kazem, Lotfi, Fariborz, Tahvildar, Seyed Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139483/
https://www.ncbi.nlm.nih.gov/pubmed/21792331
http://dx.doi.org/10.2147/CMR.S18147
_version_ 1782208464913694720
author Moslemi, Mohammad Kazem
Lotfi, Fariborz
Tahvildar, Seyed Ali
author_facet Moslemi, Mohammad Kazem
Lotfi, Fariborz
Tahvildar, Seyed Ali
author_sort Moslemi, Mohammad Kazem
collection PubMed
description PURPOSE: This study was conducted to evaluate the incidence of prostate cancer (PCa) in Iranian male patients with increased prostate-specific antigen (PSA), and normal or abnormal digital rectal examination (DRE) that underwent prostate biopsy. MATERIALS AND METHODS: From March 2006 to April 2009, a total of 346 consecutive males suspected of having PCa due to increased PSA levels underwent transrectal ultrasonography (TRUS)-guided sextant biopsy of the prostate. The total PSA (tPSA), demographic data, incidence of PCa, benign prostate hyperplasia (BPH), and prostatitis were assessed. RESULTS: The patients were divided into two groups according to their PSA values (group A serum tPSA level, 4–10 ng/mL; group B serum tPSA level, 10.1–20.0 ng/mL). Of the 346 biopsied cases, 193 cases (56%) had PCa, 80 cases (23%) had BPH, and 73 cases (21%) had prostatitis. The mean PSA and the age of the carcinoma group were significantly higher than those of the benign group (P < 0.01). The biopsy results were grouped as PCa, BPH, and prostatitis. Incidence of PCa for group A and group B cases were 115 cases (51%), and 78 cases (65%), respectively. In the case of PCa, BPH, and prostatitis, the mean PSAs were 10.02 ng/mL, 8.76 ng/mL, and 8.41 ng/mL, respectively (P < 0.40). CONCLUSION: TRUS-guided prostate biopsy and interpretation by a skilled team is highly recommended for early detection of PCa or its ruling-out. It seems that a PSA cutoff value of 4 ng/mL may be applied to the Iranian population. Although the chance of PCa is high in the PSA levels of 4–10 ng/mL, the combination of some data, like age and prostate volume, can decrease the rate of unnecessary prostate biopsies. We recommend prostate biopsy when PSA and/or DRE is elevated in symptomatic patients with obstructive and/or irritative lower urinary tract symptoms (LUTS) such as dysuria, frequency, or nocturia. Due to the very high incidence of PCa in the patients with PSA greater than 10 ng/mL, TRUS-guided biopsy is indicated, whatever the findings on DRE and/or LUTS, since the PCa detection rate is high.
format Online
Article
Text
id pubmed-3139483
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31394832011-07-26 Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience Moslemi, Mohammad Kazem Lotfi, Fariborz Tahvildar, Seyed Ali Cancer Manag Res Original Research PURPOSE: This study was conducted to evaluate the incidence of prostate cancer (PCa) in Iranian male patients with increased prostate-specific antigen (PSA), and normal or abnormal digital rectal examination (DRE) that underwent prostate biopsy. MATERIALS AND METHODS: From March 2006 to April 2009, a total of 346 consecutive males suspected of having PCa due to increased PSA levels underwent transrectal ultrasonography (TRUS)-guided sextant biopsy of the prostate. The total PSA (tPSA), demographic data, incidence of PCa, benign prostate hyperplasia (BPH), and prostatitis were assessed. RESULTS: The patients were divided into two groups according to their PSA values (group A serum tPSA level, 4–10 ng/mL; group B serum tPSA level, 10.1–20.0 ng/mL). Of the 346 biopsied cases, 193 cases (56%) had PCa, 80 cases (23%) had BPH, and 73 cases (21%) had prostatitis. The mean PSA and the age of the carcinoma group were significantly higher than those of the benign group (P < 0.01). The biopsy results were grouped as PCa, BPH, and prostatitis. Incidence of PCa for group A and group B cases were 115 cases (51%), and 78 cases (65%), respectively. In the case of PCa, BPH, and prostatitis, the mean PSAs were 10.02 ng/mL, 8.76 ng/mL, and 8.41 ng/mL, respectively (P < 0.40). CONCLUSION: TRUS-guided prostate biopsy and interpretation by a skilled team is highly recommended for early detection of PCa or its ruling-out. It seems that a PSA cutoff value of 4 ng/mL may be applied to the Iranian population. Although the chance of PCa is high in the PSA levels of 4–10 ng/mL, the combination of some data, like age and prostate volume, can decrease the rate of unnecessary prostate biopsies. We recommend prostate biopsy when PSA and/or DRE is elevated in symptomatic patients with obstructive and/or irritative lower urinary tract symptoms (LUTS) such as dysuria, frequency, or nocturia. Due to the very high incidence of PCa in the patients with PSA greater than 10 ng/mL, TRUS-guided biopsy is indicated, whatever the findings on DRE and/or LUTS, since the PCa detection rate is high. Dove Medical Press 2011-06-27 /pmc/articles/PMC3139483/ /pubmed/21792331 http://dx.doi.org/10.2147/CMR.S18147 Text en © 2011 Moslemi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Moslemi, Mohammad Kazem
Lotfi, Fariborz
Tahvildar, Seyed Ali
Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience
title Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience
title_full Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience
title_fullStr Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience
title_full_unstemmed Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience
title_short Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience
title_sort evaluation of prostate cancer prevalence in iranian male population with increased psa level, a one center experience
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139483/
https://www.ncbi.nlm.nih.gov/pubmed/21792331
http://dx.doi.org/10.2147/CMR.S18147
work_keys_str_mv AT moslemimohammadkazem evaluationofprostatecancerprevalenceiniranianmalepopulationwithincreasedpsalevelaonecenterexperience
AT lotfifariborz evaluationofprostatecancerprevalenceiniranianmalepopulationwithincreasedpsalevelaonecenterexperience
AT tahvildarseyedali evaluationofprostatecancerprevalenceiniranianmalepopulationwithincreasedpsalevelaonecenterexperience